Menu

First CAR T-Cell Therapy Approved in U.S.

The genetically modified blood cells will be used for patients with a type of acute lymphoblastic leukemia, when other treatments fail.

Aug 30, 2017
Shawna Williams

Each patient’s T-cells will be harvested from the body and genetically programmed to target leukemia cells. ALLINONEMOVIE, PIXABAYThe US Food and Drug Administration (FDA) announced today (August 30) that it has approved the first therapy involving chimeric antigen receptor (CAR) T cells for clinical use. Each dose of Novartis’s drug, Kymriah, will consist of a patient’s own white blood cells, harvested from the body and genetically programmed to seek an antigen on the surface of leukemia cells.

“We’re entering a new frontier in medical innovation with the ability to reprogram a patient’s own cells to attack a deadly cancer,” says FDA Commissioner Scott Gottlieb in a statement. “New technologies such as gene and cell therapies hold out the potential to transform medicine and create an inflection point in our ability to treat and even cure many intractable illnesses.”

Kymriah is approved for patients 25 years old and younger who have B-cell acute lymphoblastic leukemia, and whose disease has relapsed at least twice or is still detectable after other treatment. In a clinical trial, the therapy left 83 percent of such patients cancer-free after three months. STAT notes that only a few hundred patients per year may be eligible for the cell therapy. Priced at $475,000, it will be offered at just 32 sites around the country.

See “The CAR T-Cell Race

Despite the limited use of Kymriah, the approval ushers in “a new approach to the treatment of cancer and other serious and life-threatening diseases,” FDA says. Business Insider reports that at an FDA meeting last month, oncologist Tim Cripe of Nationwide Children’s Hospital called Kymriah “the most exciting thing I’ve seen in my lifetime.”

September 2018

The Muscle Issue

The dynamic tissue reveals its secrets

Marketplace

Sponsored Product Updates

StemExpress LeukopakâNow Available in Frozen Format

StemExpress LeukopakâNow Available in Frozen Format

StemExpress, a Folsom, California based leading supplier of human biospecimens, announces the release of frozen Peripheral Blood Leukopaks. Leukopaks provide an enriched source of peripheral blood mononuclear cells (PBMCs) with low granulocyte and red blood cells that can be used in a variety of downstream cell-based applications.

New Antifade Mounting Media from Vector Laboratories Enhances Immunofluorescence Applications

New Antifade Mounting Media from Vector Laboratories Enhances Immunofluorescence Applications

Vector Laboratories, a leader in the development and manufacture of labeling and detection reagents for biomedical research, introduces VECTASHIELD® Vibrance™ – antifade mounting media that delivers significant improvements to the immunofluorescence workflow.

Best Practices for Sample Preparation and Lipid Extraction from Various Samples

Best Practices for Sample Preparation and Lipid Extraction from Various Samples

Download this white paper from Bertin Technologies to learn how to extract and analyze lipid samples from various models!

Bio-Rad Launches CHT Ceramic Hydroxyapatite XT Media and Nuvia HP-Q Resin for Process Protein Purification

Bio-Rad Launches CHT Ceramic Hydroxyapatite XT Media and Nuvia HP-Q Resin for Process Protein Purification

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced the launch of two new chromatography media for process protein purification: CHT Ceramic Hydroxyapatite XT Media and Nuvia HP-Q Resin.